Skip Navigation
AHRQ--Agency for Healthcare Research and Quality: Advancing Excellence in Health Care
  • Home
  • Search for Research Summaries, Reviews, and Reports

Research Review - Final – Aug. 14, 2012

First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness


May be out of date: This report was assessed in December 2014 and some conclusions are possibly out of date.

Notice of Erratum: On August 20, 2012, Appendix O was updated to clarify that the route of administration for INVEGA SUSTENNA is IM injection (dosage 39 mg - 234 mg) and the route of administration for RISPERIDOL CONSTA is IM injection (dosage 25 mg).

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.